Sep 09, 2022
The role of sphingolipids in the pathogenesis of psoriasis
- Mateusz Matwiejuk1,
- Hanna Mysliwiec1,
- Adrian Chabowski2,
- Iwona Flisiak1
- 1Department of Dermatology and Venerology, Medical University of Bialystok;
- 2Department of Physiology, Medical University of Bialystok
Protocol Citation: Mateusz Matwiejuk, Hanna Mysliwiec, Adrian Chabowski, Iwona Flisiak 2022. The role of sphingolipids in the pathogenesis of psoriasis. protocols.io https://dx.doi.org/10.17504/protocols.io.36wgqjr8kvk5/v1
Manuscript citation:
1 Bocheńska, K.; Gabig-Cimińska M. Unbalanced Sphingolipid Metabolism and Its Implications for the Pathogenesis of Psoriasis. Molecules. 2020 Mar 3;25(5):1130. doi: 10.3390/molecules25051130. 2 Gendrisch, F.; Nováčková, A.; Sochorová , M.; Haarhaus B.; Vávrová, K.; Schempp, CM.; Wölfle, U. Gentiana lutea Extract Modulates Ceramide Synthesis in Primary and Psoriasis-Like Keratinocytes. Molecules 2020 Apr 16;25(8):1832. doi: 10.3390/molecules25081832. 3 Kozłowska, D.; Harasim-Symbor, E.; Myśliwiec, H.; Milewska, AJ.; Chabowski, A.; Flisiak, I. Serum sphingolipid level in psoriatic patients with obesity. Postepy Dermatol Alergol 2019 Dec;36(6):714-721. doi: 10.5114/ada.2019.91422. Epub 2019 Dec 30. 4 Łuczaj, W.; Wroński, A.; Domingues, P.; Rosário Domingues, M.; and Skrzydlewska E. Lipidomic Analysis Reveals Specific Differences between Fibroblast and Keratinocyte Ceramide Profile of Patients with Psoriasis Vulgaris Molecules. Clin Immunol. 2020 May;214:108397. doi: 10.1016/j.clim.2020.108397. Epub 2020 Mar 27.PMID: 32229290. 5 Myśliwiec, H.; Baran, A.; Harasim-Symbor, E.; Myśliwiec, P.; Milewska, AJ.; Chabowski, A.; Flisiak, I. Serum fatty acid profile in psoriasis and its comorbidity. Arch Dermatol Res. 2017 Jul;309(5):371-380. doi: 10.1007/s00403-017-1748-x. Epub 2017 Jun 5.PMID: 28585093. 6 Checa, A.; Xu, N.; G. Sar, D.; Haeggström, JZ.; Ståhle, M.; Wheelock, C.E. Circulating levels of sphingosine-1-phosphate are elevated in severe, but not mild psoriasis and are unresponsive to anti-TNF-α treatment. PLoS One. 2019 May 15;14(5):e0216963. doi: 10.1371/journal.pone.0216963. eCollection 2019.PMID: 31091284. 7 Jeon, S.; Song, J.; Lee, D.; Kim, G-T.; Park, S-H.; Shin, D-Y.; Shin, K-O.; Park, K.; Shim, S-M.; Park, T-S. Inhibition of sphingosine 1-phosphate lyase activates human keratinocyte differentiation and attenuates psoriasis in mice. J Lipid Res. 2020 Jan;61(1):20-32. doi: 10.1194/jlr.RA119000254. Epub 2019 Nov 5. 8 Uchida, Y.; Park, K. Ceramides in Skin Health and Disease: An Update. Am J Clin Dermatol. 2021 Nov;22(6):853-866. doi: 10.1007/s40257-021-00619-2. Epub 2021 Jul 20. 9 Lew, BL.; Cho, Y.; Kim, J.; Sim, WY.; Kim, NI. Ceramides and cell signaling molecules in psoriatic epidermis: reduced level of ceramides, PKC-alpha and JNK. J Korean Med Sci. 2006 Feb;21(1):95-9. doi: 10.3346/jkms.2006.21.1.95. 10 Jeon, S.; Song, J.; Lee, D.; Kim, GT.; Park, SH.; Shin, DY.; Shin, KO.; Park, K.; Shim, SM.; Park TS. Inhibition of sphingosine 1-phosphate lyase activates human keratinocyte differentiation and attenuates psoriasis in mice. J Lipid Res. 2020 Jan;61(1):20-32. doi: 10.1194/jlr.RA119000254. Epub 2019 Nov 5. 11 Bochenska, K.; Gabig-Cimińska, M. Unbalanced Sphingolipid Metabolism and Its Implications for the Pathogenesis of Psoriasis Molecules. Molecules. 2020 Mar 3;25(5):1130. doi: 10.3390/molecules25051130. 12 Moskot, M.; Bocheńska, K.; Jakóbkiewicz-Banecka, J.; Banecki, B.; Gabig-Cimińska, M. Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders. Int J Mol Sci. 2018 Jan 15;19(1):247. doi: 10.3390/ijms19010247. 13 Nada, HA.; Elshabrawy, MM.; Ismail, N. I.; Hassan, ET.; Jafferany, M.; Elsaie, M. L. Therapeutic implications and role of serum sphingolipids on psoriasis severity after narrow band ultraviolet B treatment: A cross sectional controlled study. Dermatol Ther. 2020 Nov;33(6):e13988. doi: 10.1111/dth.13988. Epub 2020 Jul 26. 14Kozłowska, D.; Harasim-Symbor, E.; Myśliwiec, H.; Milewska, AJ.; Chabowski, A.; Flisiak I. Lipid profile disturbances may predispose psoriatic patients to liver dysfunction. Postepy Dermatol Alergol. 2021 Apr;38(2):310-318. doi: 10.5114/ada.2021.106209. Epub 2021 May 22. 15 Majumdar, I.; Mastrandrea L. D. Endocrine. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. 2012 Jun;41(3):442-9. doi: 10.1007/s12020-011-9589-4. Epub 2012 Jan 7. 16 Summers, SA.; Chaurasia, B.; Holland, W.L. Metabolic Messengers: ceramides. Nat Metab. 2019 Nov;1(11):1051-1058. doi: 10.1038/s42255-019-0134-8. Epub 2019 Oct 24. 17 Hadas, Y.; Vincek, A.S.; Youssef, E.; Żak, M.M.; Chepurko, E.; Sultana, N.; Sharkar, MTK.; Guo, N.; Komargodski, R.; Kurian, AA.; Kaur, K.; Magadum, A.; Fargnoli, A.; Katz, MG.; Hossain, N.; Kenigsberg, E.; Dubois, NC.; Schadt, E.; Hajjar, R.; Eliyahu, E.; Zangi L. Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction. Circulation. 2020 Mar 17;141(11):916-930. doi: 10.1161/CIRCULATIONAHA.119.041882. Epub 2020 Jan 29. 18 Poss, AM.; Maschek, J.A.; Cox, JE.; Hauner, B.J.; Hopkins, PN.; Hunt, SC.; Holland, WL.; Summers, SA.; Playdon, M.C. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J Clin Invest. 2020 Mar 2;130(3):1363-1376. doi: 10.1172/JCI131838. 19 Kovilakath, A.; Jamil, M.; Cowart L.A. Sphingolipids in the Heart: From Cradle to Grave. Front Endocrinol (Lausanne). 2020 Sep 15;11:652. doi: 10.3389/fendo.2020.00652. eCollection 2020. 20 Myśliwiec, H.; Baran, A.; Harasim-Symbor, E.; Choromańska, B.; Myśliwiec, P.; Milewska, A.J.; Chabowski, A.; Flisiak, I. Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Arch Dermatol Res. 2017 Mar;309(2):79-86.doi: 10.1007/s00403-016-1709-9. Epub 2016 Dec 17. 21 Borodzicz, S.; Rudnicka, L.; Mirowska-Guzel, D.; Cudnoch-Jedrzejewska A.; The role of epidermal sphingolipids in dermatologic diseases. Lipids Health Dis. 2016 Jan 19;15:13. doi: 10.1186/s12944-016-0178-7.PMID: 26786937. 22 Holleran, WM.; Takagi,Y.; Uchida, Y.; Epidermal sphingolipids: metabolism, function, and roles in skin disorders. Am J Clin Dermatol. 2003;4(2):107-29. doi: 10.2165/00128071-200304020-00004.PMID: 12553851. 23 Gao, Y.; Lu, J.; Bao, X.; Yi, X.; Peng, C.; Chen, W.; Zhen, T.; Shi, Y.; Xing, K.; Zhu, S.; Ding Y.; Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation. Exp Biol Med (Maywood). 2021 Jun;246(11):1253-1262. doi: 10.1177/1535370221993424. Epub 2021 Feb 27. 24 Li, L.; Chuan-Jian, L.; Ling, H.; Jing-Wen, D.; Ze-Hui, H.; Yu-Hong, Y.; Zhong-Zhao, Z.; Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry. Oncotarget. 2017 Oct 6;8(56):95931-95944. doi: 10.18632/oncotarget.21562. eCollection 2017 Nov 10. 25 Kendall, A.C.; Nicolaou, A. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid Res. 2013 Jan;52(1):141-64. doi: 10.1016/j.plipres.2012.10.003. Epub 2012 Nov 1.PMID: 23124022. 26Farwanah, H.; Raith, K.; Neubert, RHH.; Wohlrab J. Ceramide profiles of the uninvolved skin in atopic dermatitis and psoriasis are comparable to those of healthy skin. Arch Dermatol Res. 2005 May;296(11):514-21. doi: 10.1007/s00403-005-0551-2. Epub 2005 Apr 1. 27 Moon, Sh.; Kim, JY.;, Song, EH.; Shin, MK.; Cho, YH.; Kim, NI.; Altered levels of sphingosine and sphinganine in psoriatic epidermis. Ann Dermatol. 2013 Aug;25(3):321-6. doi: 10.5021/ad.2013.25.3.321. Epub 2013 Aug 13. 28 Zeng, C.; Wen, B.; Hou, G.; Lei, L.; Mei, Z.; Jia, H.; Chen, X.; Zhu, W.; Li, J.; Kuang, Y.; Weiqi, Z.; Su, J.; Liu, S.; Peng, C.; Chen, X. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis. Gigascience. 2017 Oct 1;6(10):1-11. doi: 10.1093/gigascience/gix087. 29 Pang, X.; Lin, K.; Liu, W.; Zhang, P.; Zhu, S.; Characterization of the abnormal lipid profile in Chinese patients with psoriasis. Int J Clin Exp Pathol. 2015 Nov 1;8(11):15280-4. eCollection 2015. 30 Ferretti, G.; Bacchetti, T.; Campanati, A.; Simonetti, O.; Liberati, G.; Offidani, A.; Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012 Jan;166(1):204-7. doi: 10.1111/j.1365-2133.2011.10539.x. 31 Altekin, ER.; Koç, S.; Karakaş, MS.; Yanıkoğlu, A.; Başarıcı, I.; Demir, I.; Alpsoy, E. Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis. Turk Kardiyol Dern Ars. 2012 Oct;40(7):574-80. doi: 10.5543/tkda.2012.54920. 32 Wang, B.; Deng, H.; Hu, Y.; Han, L.; Huang, Q.; Fang, X.; Yang, K.; Wu, S.; Zheng, Z.; Yawalkar, N.; Zhang, Z.; Yan, K.The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio. Arthritis Res Ther. 2022 Jan 7;24(1):17. doi: 10.1186/s13075-021-02715-4. 33 Souto-Carneiro, M.; Tóth, L.; Behnisch, R.; Urbach, K.; Klika, KD.; Carvalho, RA.; Lorenz, HM.; Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. Ann Rheum Dis. 2020 Apr;79(4):499-506. doi: 10.1136/annrheumdis-2019-216374. Epub 2020 Feb 20. 34 Shao, S.; Chen, J.; Swindell, WR.; Tsoi, LC.; Xing, X.; Ma, F.; Uppala, R.; Sarkar, MK.; Plazyo, O.; Billi, AC.; Wasikowski, R.; Smith, KM.; Honore, P.; Scott, VE.; Maverakis, E.; Kahlenberg, JM.; Wang, G.; Ward, NL.; Harms, PW.; Gudjonsson, JE.; Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight. 2021 Oct 22;6(20):e151911. doi: 10.1172/jci.insight.151911. 35 Sorokin, AV.; Domenichiello, AF.; Dey, AK.; Yuan, ZX.; Goyal, A.; Rose, SM.; Playford, MP.; Ramsden, CE.; Mehta, NN.; Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol. 2018 Jul;138(7):1518-1528. doi: 10.1016/j.jid.2018.02.003. Epub 2018 Feb 15. 36 Tyrrell, VJ.; Ali, F.; Boeglin, WE.; Andrews, R.; Burston, J.; Birchall, JC.; Ingram, JR.; Murphy, RC.; Piguet, V.; Brash, AR.; O'Donnell, VB.; Thomas, Cp.Lipidomic and transcriptional analysis of the linoleoyl-omega-hydroxyceramide biosynthetic pathway in human psoriatic lesions. J Lipid Res. 2021;62:100094.doi: 10.1016/j.jlr.2021.100094. Epub 2021 Jun 22. 37 Łuczaj, W.; Dobrzyńska, I.; Wroński, A.; Domingues, MR.; Domingues, P.; Skrzydlewska, E. Cannabidiol-Mediated Changes to the Phospholipid Profile of UVB-Irradiated Keratinocytes from Psoriatic Patients. Int J Mol Sci. 2020 Sep 9;21(18):6592. doi: 10.3390/ijms21186592. 38 Yamamoto, K.; Miki, Y.; Sato, H.; Nishito, Y.; Gelb, MH.; Taketomi, Y.; Murakami, M.Expression and Function of Group IIE Phospholipase A2 in Mouse Skin. J Biol Chem. 2016 Jul 22;291(30):15602-13. doi: 10.1074/jbc.M116.734657. Epub 2016 May 23. 39 Kim, D.; Kim, HJ.; Baek, JO.; Roh, JY.; Jun, HS.Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1/ROCK2/PI3K/AKT Signaling Pathway. Int J Mol Sci. 2021 Oct 5;22(19):10777. doi: 10.3390/ijms221910777. 40 Myśliwiec, H.; Harasim-Symbor, E.; Baran, A.; Szterling-Jaworowska, M.; Milewska, AJ.; Chabowski, A.; Flisiak, I. Abnormal serum fatty acid profile in psoriatic arthritis. Arch Med Sci. 2019 Oct;15(6):1407-1414. doi: 10.5114/aoms.2019.89451. Epub 2019 Nov 3. 41 Ilanbey, B.; Elmas, ÖF.; Sözmen, EY.; Günay, Ü.; Demirbaş, A.; Atasoy, M.; Türsen, Ü.; Lotti T. A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turk J Med Sci. 2021 Oct 21;51(4):2318-2323. doi: 10.3906/sag-2101-137. 42 Gaire, BP.; Lee, CH.; Kim, W.; Sapkota, A.; Lee, DY.; Choi, JW. Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages. Cells. 2020 Jul 22;9(8):1753. doi: 10.3390/cells9081753. 43 Ji, M.; Xue, N.; Lai, F.; Zhang, X.; Zhang, S.; Wang, Y.; Jin, J.; Chen, X. Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment. Biol Pharm Bull. 2018 Apr 1;41(4):592-596. doi: 10.1248/bpb.b17-00939. Epub 2018 Feb 7. 44 Ogawa, E.; Owada, Y.; Ikawa, S.; Adachi, Y.; Egawa, T.; Nemoto, K.; Suzuki, K.; Hishinuma, T.; Kawashima, H.; Kondo, H.; Muto, M.; Aiba, S.; Okuyama, R. Epidermal FABP (FABP5) Regulates Keratinocyte Differentiation by 13(S)-HODE-Mediated Activation of the NF-jB Signaling Pathway. J Invest Dermatol. 2011 Mar;131(3):604-12. doi: 10.1038/jid.2010.342. Epub 2010 Nov 11. 45 Hong, JH.; Youm, JK.; Kwon, MJ.; Park, BD.; Lee, YM.; Lee, SI.; Shin, DM.; Lee SH. K6PC-5, a Direct Activator of Sphingosine Kinase 1, Promotes Epidermal Differentiation Through Intracellular Ca2+ Signaling. J Invest Dermatol. 2008 Sep;128(9):2166-78. doi: 10.1038/jid.2008.66. Epub 2008 Apr 3.PMID: 18385762. 46 Shou, Y.; Yang, L.; Yang, Y.; Xu, J. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 2021 Oct 27;12(11):1009. doi: 10.1038/s41419-021-04284-5. 47 Utsunomiya, A.; Chino, T.; Utsunomiya, N.; Luong, VH.; Tokuriki, A.; Naganuma, T.; Arita, M.; Higashi, K.; Saito, K.; Suzuki, N.; Ohara, A.; Sugai, M.; Sugawara, K.; Tsuruta, D.; Oyama, N.; Hasegawa, M. Homeostatic Function of Dermokine in the Skin Barrier and Inflammation. J Invest Dermatol. 2020 Apr;140(4):838-849.e9. doi: 10.1016/j.jid.2019.09.011. Epub 2019 Oct 25. 48 Del Rosso, JQ. Ceramide- and Keratolytic-containing Body Cleanser and Cream Application in Patients with Psoriasis: Outcomes from a Consumer Usage Study. J Clin Aesthet Dermatol. 2019 Jul;12(7):18-21. Epub 2019 Jul 1. 49 Choi, MJ.; Maibach, HI. Role of Ceramides in Barrier Function of Healthy and Diseased Skin. Am J Clin Dermatol. 2005;6(4):215-23. doi: 10.2165/00128071-200506040-00002.PMID: 16060709. 50 Yokose, U.; Ishikawa, J.; Morokuma, Y.; Naoe, A.; Inoue, Y.; Yasuda, Y.; Tsujimura, H.; Fujimura, T.; Murase, T.; Hatamochi, A.The ceramide [NP]/[NS] ratio in the stratum corneum is a potential marker for skin properties and epidermal differentiation. BMC Dermatol. 2020 Aug 31;20(1):6. doi: 10.1186/s12895-020-00102-1. 51 Cho, Y.; Lew, BL.; Seong, K.; Kim, NI. An Inverse Relationship Between Ceramide Synthesis and Clinical Severity in Patients with Psoriasis. J Korean Med Sci. 2004 Dec;19(6):859-63. doi: 10.3346/jkms.2004.19.6.859. 52 Tessema, En.; Gebre-Mariamb, T.; Paulosb, G.; Wohlrab, J.; Neuberta, RHH. Delivery of oat-derived phytoceramides into the stratum corneum of the skin using nanocarriers: Formulation, characterization and in vitro and ex-vivo penetration studies. Eur J Pharm Biopharm. 2018 Jun;127:260-269. doi: 10.1016/j.ejpb.2018.02.037. Epub 2018 Mar 6. 53 Egger, AN.; Rajabi‐Estarabadi, A.; Williams, NM.; Resnik, SR.; Fox, JD.; Wong, LL.; Jozic, I. The importance of caveolins and caveolae to dermatology: Lessons from the caves and beyond. Exp Dermatol. 2020 Feb;29(2):136-148. doi: 10.1111/exd.14068. Epub 2020 Jan 10. 54 Geilen, CC.; Bektas, M.; Wieder, T.; Orfanos, CE. The vitamin D3 analogue, calcipotriol, induces sphingomyelin hydrolysis in human keratinocytes. FEBS Lett. 1996 Jan 2;378(1):88-92. doi: 10.1016/0014-5793(95)01421-7.PMID: 8549810. 55 Syed, SN.; Weigert, A.; Brüne, B. Sphingosine Kinases are Involved in Macrophage NLRP3 Inflammasome Transcriptional Induction. Int J Mol Sci. 2020 Jul 2;21(13):4733. doi: 10.3390/ijms21134733. 56 Lasa, JS.; Olivera, PA.; Bonovas, S.; Danese, S.; Peyrin Biroulet L. Safety of S1P Modulators in Patients with Immune Mediated Diseases: A Systematic Review and Meta Analysis. Drug Saf. 2021 Jun;44(6):645-660. doi: 10.1007/s40264-021-01057-z. Epub 2021 Mar 5. 57 Schuster, C.; Huard, A.; Sirait-Fischer, E.; Dillmann, C.; Brüne, B.; Weigert, A. S1PR4-dependent CCL2 production promotes macrophage recruitment in a murine psoriasis model. Eur J Immunol. 2020 Jun;50(6):839-845. doi: 10.1002/eji.201948349. Epub 2020 Feb 18. 58 Sordillo, PP.; Sordillo, DC.; Helson, L. Review: The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. In Vivo. Nov-Dec 2015;29(6):619-36. 59 Setyawan, J.; Mu, F.; Yarur, A.; Zichlin, Ml.; Yang, H.; Fernan, C.; Billmyer, E.; Downes, N.; Azimi, N.; Strand, V. Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases. Clin Ther. 2021 Aug;43(8):1392-1407.e1.doi: 10.1016/j.clinthera.2021.06.008. Epub 2021 Jul 6. 60 Rujimongkon, K.; Ampawong, S.; Reamtong, O.; Buaban, T.; Aramwit, P. The therapeutic effects of Bombyx mori sericin on rat skin psoriasis through modulated epidermal immunity and attenuated cell proliferation. J Tradit Complement Med. 2021 Jul 1;11(6):587-597. doi: 10.1016/j.jtcme.2021.06.007. eCollection 2021 Nov. 61 Okura, I.; Kamataa, M.; Asanoc, Y.; Mitsuic, A.; Shimizua, T.; Satoc, S.; Tadaa, Y. Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing T cells in secondary lymph nodes. J Dermatol Sci. 2021 May;102(2):116-125. doi: 10.1016/j.jdermsci.2021.04.004. Epub 2021 Apr 15. 62 Shin, Sh.; Kim, HY.; Yoon, HS.; Park, WJ.; Adams, DR.; Pyne, Nj.; Pyne, S.; Park, JW. A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes. Int J Mol Sci. 2020 Nov 8;21(21):8371. doi: 10.3390/ijms21218371. 63 Zhang, Z.; Zi, Z.; Lee, EE.; Zhao, J.; Contreras, DC.; South, Ap.; Abel, ED.; Chong, BF.; Vandergriff, T.; Hosler, GA.; Scherer, PE.; Mettlen, M.; Rathmell, JC.; DeBerardinis, RJ.; Wang, RC.; Differential Glucose Requirement in Skin Homeostasis and Injury Identifies a Therapeutic Target for Psoriasis. Nat Med. 2018 May;24(5):617-627. doi: 10.1038/s41591-018-0003-0. Epub 2018 Apr 16. 64 Li, X.; Yang, Q.; Zheng, J.; Gu, H.; Chen, K.; Jin, H.; He, C.; Xu, A.; Xu, J.; Zhang, J.; Yu, W.; Guo, Z.; Xiong, L.; Song, Y.; Zhang, L.Efficacy and safety of a topical moisturizer containing linoleic acid and ceramide for mild‐to‐moderate psoriasis vulgaris: A multicenter randomized controlled trial. Dermatol Ther. 2020 Nov;33(6):e14263. doi: 10.1111/dth.14263. 65 Liu, F.; Wang, S.; Liu, B.; Wang, Y.; Tan, W. (R)-Salbutamol Improves Imiquimod-Induced Psoriasis-Like Skin Dermatitis by Regulating the Th17/Tregs Balance and Glycerophospholipid Metabolism. Cells. 2020 Feb 24;9(2):511. doi: 10.3390/cells9020511. 66 Simoni, Y.; Diana, J.; Ghazarian, L.; Beaudoin, L.; Lehuen, A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol. 2013 Jan;171(1):8-19. doi: 10.1111/j.1365-2249.2012.04625.x. 67 Lee, DD.; Stojadinovic, O.; Krzyzanowska, A.; Vouthounis, C.; Blumenberg, M.; Tomic-Canic, M. Retinoid-Responsive Transcriptional Changes in Epidermal Keratinocytes. J Cell Physiol. 2009 Aug;220(2):427-439. doi: 10.1002/jcp.21784. 68 Bochenska, K.; Moskot, M.; Malinowska, M.; Jakóbkiewicz-Banecka, J.; Szczerkowska-Dobosz, A.; Purzycka-Bohdan, D.; Plenkowska, J.; Słominski B.; Gabig-Ciminska, M. Lysosome Alterations in the Human Epithelial Cell Line HaCaT and Skin Specimens: Relevance to Psoriasis. Int J Mol Sci. 2019 May 7;20(9):2255. doi: 10.3390/ijms20092255. 69 Breiden, B.; Sandhof, K. The role of sphingolipid metabolism in cutaneous permeability barrier formation. Biochim Biophys Acta. 2014 Mar;1841(3):441-52. doi: 10.1016/j.bbalip.2013.08.010. Epub 2013 Aug 15. 70 Motta, S.; Monti, M.; Sesana, S.; Mellesi, L.; Ghidoni, R.; Caputo, R. Abnormality of Water Barrier Function in Psoriasis. Role of ceramide fractions. Arch Dermatol. 1994 Apr;130(4):452-6. 71 Hong, KK.; Cho, HR.; Ju, WC.; Cho, Y.; Kim, NI. A Study on Altered Expression of Serine Palmitoyltransferase and Ceramidase in Psoriatic Skin Lesion. J Korean Med Sci. 2007 Oct;22(5):862-7. doi: 10.3346/jkms.2007.22.5.862. 72 Alessandrini, F.; Pfister, S.; Kremmer, E.; Gerber, JK.; Ring, J.; Behrendt, H. Alterations of Glucosylceramide-b-Glucosidase Levels in the Skin of Patients with Psoriasis Vulgaris. J Invest Dermatol. 2004 Dec;123(6):1030-6. doi: 10.1111/j.0022-202X.2004.23469.x. 73 Tawada, C.; Kanoh, H.; Nakamura, M.; Mizutani, Y.; Fujisawa, T.; Banno, Y.; Seishima, M. Interferon-c Decreases Ceramides with Long-Chain Fatty Acids: Possible Involvement in Atopic Dermatitis and Psoriasis. J Invest Dermatol. 2014 Mar;134(3):712-718. doi: 10.1038/jid.2013.364. Epub 2013 Sep 5.
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: September 06, 2022
Last Modified: September 09, 2022
Protocol Integer ID: 69618
Keywords: Psoriasis, ceramide, sphingolipid, S1P-lyase, Sphingosine Lipid signaling, S1P-lyase, Sphingosine 1-phosphate, Sphingosine kinase, Sphingomyelin, Ceramide S1P receptor
Abstract
Psoriasis is complexed, chronic, immunologically mediated disease, which involves skin and joints. Psoriasis is commonly connected with numerous other diseases such as liver diseases, metabolic syndrome, impaired glucose tolerance, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease. Interestingly, comorbidities of psoriasis are attention-grabbing issue, additionally it can cause impairment of quality of life and may be associated with depressive disorders. Altered levels of ceramides in psoriatic skin, may lead to an anti-apoptotic and pro-proliferative states, consequently conducting to over-proliferation of keratinocytes and the development of skin lesions. Pathophysiology of psoriasis and its comorbidities is not fully understood yet. Sphingolipids, including ceramides, and their disturbed metabolism, may be the link between psoriasis and its comorbidities. Overall, the goal of this review was to discuss the role of sphingolipid disturbances in psoriasis and its comorbidities. PubMed was searched from February to the beginning of the May 2022. The systematic review included 73 eligible original articles.